Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Bre (Q61624905)
Jump to navigation
Jump to search
scientific article published on 01 November 2005
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Bre |
scientific article published on 01 November 2005 |
Statements
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31 (English)
Eleftherios P Mamounas
Elizabeth Tan-Chiu
Edward Romond
Michael Ewer
Deborah Keefe
Ann Brown
Louis Fehrenbacher
Priya Rastogi
Norman Wolmark
John Bryant
Charles E Geyer
Richard P Shannon
Victor G Vogel